Page 25 - Research Models News Today

Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) was the recipient of a significant increase in short interest in April. As of April 30th, there was short interest totalling 1,540,000 shares, an increase of 11.6% from the April 15th total of 1,380,000 shares. Based on an average daily volume of 580,200 shares, the short-interest […]

Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) EVP Joseph W. Laplume sold 345 shares of the firm’s stock in a transaction dated Monday, May 15th. The shares were sold at an average price of $190.39, for a total transaction of $65,684.55. Following the completion of the sale, the executive vice president now owns […]

Charles River Laboratories International (NYSE:CRL – Get Rating) had its target price decreased by Credit Suisse Group from $260.00 to $255.00 in a research note released on Friday morning, The Fly reports. CRL has been the subject of a number of other research reports. Jefferies Financial Group lowered their price objective on Charles River Laboratories […]

Pinebridge Investments L.P. grew its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) by 24.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 70,020 shares of the medical research company’s stock after purchasing an additional […]

Nicholas Company Inc. trimmed its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) by 2.0% in the 4th quarter, HoldingsChannel reports. The firm owned 49,711 shares of the medical research company’s stock after selling 1,040 shares during the period. Nicholas Company Inc.’s holdings in Charles River Laboratories International were worth […]

Charles River Laboratories International (NYSE:CRL – Get Rating) had its price target lowered by Deutsche Bank Aktiengesellschaft from $260.00 to $250.00 in a research report released on Friday morning, The Fly reports. Several other brokerages also recently weighed in on CRL. Credit Suisse Group reduced their price objective on shares of Charles River Laboratories International […]

EverSource Wealth Advisors LLC lessened its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) by 43.9% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,597 shares of the medical research company’s stock after selling 1,250 shares […]

In 2022, the US Animal Model Market size was valued at approximately US$ 947.3 million. From 2023 to 2033, demand for Animal Models in the United States is expected to rise at a 4.3% CAGR. The value of demand for Animal Models in the United States is expected to reach US$ 1,487.9 million by 2033. According to Future...

California Public Employees Retirement System cut its position in Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) by 1.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 111,975 shares of the medical research company’s stock after selling 1,578 shares during […]

Charles River Laboratories International (NYSE:CRL – Get Rating) had its price objective reduced by research analysts at Wells Fargo & Company from $290.00 to $280.00 in a note issued to investors on Friday, The Fly reports. Wells Fargo & Company‘s price target would indicate a potential upside of 43.04% from the company’s previous close. CRL […]